Menu
×
Folly Beach Library
9 a.m. - 5:30 p.m.
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
West Ashley Library
9 a.m. – 7 p.m.
Phone: (843) 766-6635
Wando Mount Pleasant Library
9 a.m. – 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 6 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. – 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. – 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. – 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. – 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. – 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. – 8 p.m.
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
9 a.m. - 4 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. – 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. – 7 p.m.
Phone: (843) 722-7550
Baxter-Patrick James Island
9 a.m. – 8 p.m.
Phone: (843) 795-6679
Main Library
9 a.m. – 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. – 8 p.m.
Phone: (843) 805-6892
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Today's Hours
Folly Beach Library
9 a.m. - 5:30 p.m.
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
West Ashley Library
9 a.m. – 7 p.m.
Phone: (843) 766-6635
Wando Mount Pleasant Library
9 a.m. – 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 6 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. – 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. – 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. – 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. – 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. – 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. – 8 p.m.
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
9 a.m. - 4 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. – 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. – 7 p.m.
Phone: (843) 722-7550
Baxter-Patrick James Island
9 a.m. – 8 p.m.
Phone: (843) 795-6679
Main Library
9 a.m. – 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. – 8 p.m.
Phone: (843) 805-6892
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Patron Login
menu
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
- Author(s): Fakhrolmobasheri M;Fakhrolmobasheri M; Abhari AP; Abhari AP; Manshaee B; Manshaee B; Heidarpour M; Heidarpour M; Shafie D; Shafie D; Mohammadbeigi E; Mohammadbeigi E; Mozafari AM; Mozafari AM; Mozafari AM; Mazaheri-Tehrani S; Mazaheri-Tehrani S; Mazaheri-Tehrani S
- Source:
Acta diabetologica [Acta Diabetol] 2023 Feb; Vol. 60 (2), pp. 191-202. Date of Electronic Publication: 2022 Oct 20.- Publication Type:
Meta-Analysis; Systematic Review; Journal Article- Language:
English - Source:
- Additional Information
- Source: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
- Publication Information: Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991- - Subject Terms: Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/complications ; Insulin Resistance* ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Metformin*/therapeutic use; Humans ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/pharmacology ; Glucose ; Sodium/therapeutic use
- Abstract: Aim: Recent studies have indicated that Sodium-GLucose co-Transporter 2 Inhibitors (SGLT2Is) may increase insulin sensitivity (IS); however, these results are heterogeneous and need to be systematically assessed.
Method: We searched MEDLINE/PubMed, Embase, Web of Science, Scopus, Cochrane Library, Ovid, and ProQuest using a predefined search query. Randomized clinical trials on SGLT2Is with a passive control group or metformin controlled group were included. Risk of bias assessment was performed using the Cochrane risk of bias assessment tool. Meta-analysis was performed separately on studies with type 2 diabetes mellitus (T2DM) population and studies with non-T2DM population and also for passive- and active-controlled studies using standardized mean difference (SMD) as the measure of the effect size. Subgroup analysis was performed according to different types of SGLT2Is. Meta-regression analysis was performed according to the dose and duration of intervention.
Results: Twenty-two studies (6 on non-T2DM population) with a total of 1421 (243 non-T2DM) patients were included. Six studies (3 on T2DM and 3 on non-T2DM) were controlled by metformin, and others were passively controlled. SGLT2Is could significantly increase IS in T2DM patients (SMD = 0.72 [0.32-1.12]). SGLT2Is could reduce insulin resistance in non-T2DM population, but this was not significant. SGLT2Is were not inferior to metformin in reducing insulin resistance. Subgroup analysis indicated that dapagliflozin could significantly increase IS, but empagliflozin was not associated with significant improvement in IS. Meta-regression analysis indicated no effect for dose but duration of SGLT2I administration on IS.
Conclusion: SGLT2Is, particularly dapagliflozin, could increase IS. These results need to be consolidated by further studies.
(© 2022. Springer-Verlag Italia S.r.l., part of Springer Nature.) - References: Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al (2020) Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 76(25):2982–3021.
Hsia DS, Grove O, Cefalu WT (2017) An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 24(1):73–79.
Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17(12):761–772.
Tamez-Perez HE, Delgadillo-Esteban E, Soni-Duque D, Hernández-Coria MI, Tamez-Peña AL (2017) SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study. J Diabetes Metab Disord 16:27.
Li C, Luo J, Jiang M, Wang K (2022) The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol 13:838277.
Xu L, Ota T (2018) Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte 7(2):121–128.
Higgins JPT, Thomas J, Chandler J et al (eds) (2022) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. Available from www.training.cochrane.org/handbook .
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71.
Cai M, Shao X, Xing F et al (2022) Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial. Diabetes Obes Metab 24(2):312–320.
Chehrehgosha H, Sohrabi MR, Ismail-Beigi F et al (2021) Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther 12(3):843–861.
Daniele G, Xiong J, Solis-Herrera C et al (2016) Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39(11):2036–2041.
Elkind-Hirsch KE, Seidemann E, Harris R (2020) A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM 2(3). Available from: https://www.ajogmfm.org/article/S2589-9333(20)30083-5/fulltext.
González-Ortiz M, Méndez-Del Villar M, Martínez-Abundis E, Ramírez-Rodríguez AM (2018) Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol 43(3):229–235.
Hao Z, Sun Y, Li G, Shen Y, Wen Y, Liu Y (2022) Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. BMC Endocr Disord 22(1):37.
Hattori S (2018) Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr 10(1):93.
Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J et al (2019) Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol (Oxf) 90(6):805–813.
Jiang LL, Zhang P, Liu BL et al (2021) Effects of dapagliflozin adjunct to insulin on glycemic variations in patients with newly diagnosed type 2 diabetes: a randomized, controlled, open-labeled trial. Biomed Res Int 2021:6618257.
Kahl S, Gancheva S, Straßburger K et al (2020) Empagliflozin Effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43(2):298–305.
Koshizaka M, Ishikawa K, Ishibashi R et al (2019) Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab 21(8):1990–1995.
Kullmann S, Hummel J, Wagner R et al (2022) Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care 45(2):398–406.
Latva-Rasku A, Honka MJ, Kullberg J et al (2019) The SGLT2 inhibitor Dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 42(5):931–937.
Liao X, Wang X, Li H et al (2016) Sodium-glucose cotransporter 2 (SGLT2) inhibitor increases circulating zinc-Α2-glycoprotein levels in patients with Type 2 Diabetes. Sci Rep 6(1):32887.
Matthaei S, Bowering K, Rohwedder K et al (2015) Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metabolism 17(11):1075–1084.
Merovci A, Mari A, Solis C et al (2015) Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab 100(5):1927–1932.
Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124(2):509–514.
Mudaliar S, Henry RR, Boden G et al (2014) Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin. Diabetes Technol Ther 16(3):137–144.
Phrueksotsai S, Pinyopornpanish K, Euathrongchit J et al (2021) The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 36(10):2952–2959.
Ramírez-Rodríguez AM, González-Ortiz M, Martínez-Abundis E (2020) Effect of Dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes 128(8):506–511.
Shigiyama F, Kumashiro N, Miyagi M et al (2017) Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol 16(1):84.
Takahashi H, Kessoku T, Kawanaka M et al (2022) Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun 6(1):120–132.
Tanaka K, Takahashi H, Katagiri S et al (2020) Combined effect of canagliflozin and exercise training on high-fat diet-fed mice. Am J Physiol-Endocrinol Metabolism 318(4):E492-503.
Swe MT, Thongnak L, Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Lungkaphin A (2020) Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats. J Endocrinol 245(2):193–205.
Solinas G, Becattini B (2017) JNK at the crossroad of obesity, insulin resistance, and cell stress response. Molecular Metabolism 6(2):174–184.
Yokono M, Takasu T, Hayashizaki Y et al (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727:66–74.
Bolinder J, Ljunggren Ö, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16(2):159–169.
Joannides CN, Mangiafico SP, Waters MF, Lamont BJ, Andrikopoulos S (2017) Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metab 19(8):1135–1146.
Obata A, Kubota N, Kubota T et al (2016) Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology 157(3):1029–1042.
Park S, Kim DS, Daily JW (2011) Central infusion of ketone bodies modulates body weight and hepatic insulin sensitivity by modifying hypothalamic leptin and insulin signaling pathways in type 2 diabetic rats. Brain Res 1401:95–103.
Garcia E, Shalaurova I, Matyus SP et al (2020) Ketone bodies are mildly elevated in subjects with type 2 diabetes mellitus and are inversely associated with insulin resistance as measured by the lipoprotein insulin resistance index. J Clin Med 9(2):321.
Kashiwaya Y, King MT, Veech RL (1997) Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart. Am J Cardiol 80(3):50A-64A.
Veech RL (2004) The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 70(3):309–319.
Wang X, Wang Z, Liu D et al (2022) Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and gut microbiota dysbiosis in mice with diabetic cardiovascular disease. Front Pharmacol, 13. https://doi.org/10.3389/fphar.2022.839640.
Chen YY, Wu TT, Ho CY et al (2019) Dapagliflozin prevents NOX- and SGLT2-dependent oxidative stress in lens cells exposed to fructose-induced diabetes mellitus. Int J Mol Sci 20(18):4357.
Hussein AM, Eid EA, Taha M, Elshazli RM, Bedir RF, Lashin LS (2020) Comparative study of the effects of GLP1 Analog and SGLT2 inhibitor against diabetic cardiomyopathy in Type 2 diabetic rats: possible underlying mechanisms. Biomedicines 8(3):43.
Trnovska J, Svoboda P, Pelantova H et al (2021) Complex positive effects of SGLT-2 inhibitor Empagliflozin in the liver, kidney and adipose tissue of hereditary hypertriglyceridemic rats: possible contribution of attenuation of cell senescence and oxidative stress. Int J Mol Sci 22(19):10606.
Mayans L (2015) Metabolic syndrome: insulin resistance and prediabetes. FP Essent 435:11–16. - Contributed Indexing: Keywords: Dapagliflozin; Empagliflozin; Insulin resistance; Insulin sensitivity; Sodium–glucose cotransporter 2 inhibitors
- Accession Number: 0 (Hypoglycemic Agents)
1ULL0QJ8UC (dapagliflozin)
0 (Sodium-Glucose Transporter 2 Inhibitors)
9100L32L2N (Metformin)
IY9XDZ35W2 (Glucose)
9NEZ333N27 (Sodium) - Publication Date: Date Created: 20221020 Date Completed: 20230123 Latest Revision: 20230123
- Publication Date: 20230123
- Accession Number: 10.1007/s00592-022-01981-1
- Accession Number: 36264350
- Source:
Contact CCPL
Copyright 2022 Charleston County Public Library Powered By EBSCO Stacks 3.3.0 [350.3] | Staff Login
No Comments.